China’s state-owned vaccine manufacturer Sinopharm was found to have successfully prevented symptomatic infections of COVID-19, Bloomberg reported.
- Two inactivated vaccines made by Sinopharm deterred symptomatic infections by 78.1% and 72.8%.
- The late-stage trial covered 40,832 volunteers across the United Arab Emirates, Bahrain, Egypt, and Jordan.
- Volunteers were split into three groups — two groups for the two vaccines, and another given placebo shots. Doses were given three weeks apart.
- Two weeks after administering both doses, infections were reported in 26 of the volunteers given the WIV04 vaccine, 21 of those given HBO2, and 95 given the placebo shot.
- There were no reported severe infections among the volunteers, based on the results submitted on March 17.
- Most or nearly 85% of the volunteers were men, while less than 2% were over the age of 60.
- The vaccines manufactured by Sinopharm unit China National Biotec Group Co.
- Findings were released in the May 26 Journal of the American Medical Association (JAMA).
1099: HKG is down 2.45%